Introduction {#Sec1}
============

The incidence of gastrointestinal (GI) malignancy is almost 30% worldwide, with high cancer-related mortality \[[@CR1], [@CR2]\]. Aging is one of the most significant risk factors for the incidence and mortality in malignancy, usually with an exponential increase \[[@CR2], [@CR3]\]. Although there is great development in oncological treatment, surgical resection is still the main curable method \[[@CR4]\]. However, for elderly oncologic patients, the incidence of postoperative complications still needs attention due to the nutrition status and potential comorbidities \[[@CR5]\].

Sarcopenia was first proposed by Rosenberg in 1989 and was defined as a disease of skeletal muscle mass decline with age and was previously referred to as age-related sarcopenia \[[@CR6], [@CR7]\]. The incidence of sarcopenia is 20% in healthy people under 70 years of age, and its incidence is more than 50% after age 80 \[[@CR8]\]. An epidemiological survey found that the incidence of muscle reduction in healthy elderly Chinese was 4.1--11.5%. A Japanese epidemiological study found that 14.2% of men and 22.1% of women in the elderly age range had muscle reduction \[[@CR9]\]. There are many causes of sarcopenia, such as skeletal muscle disuse, endocrine changes, chronic consumptive diseases, systemic inflammatory response, insulin resistance, and malnutrition \[[@CR10], [@CR11]\]. GI cancer is often accompanied by an eating disorder and vomiting, coupled with increased metabolic consumption in the oncological condition, and the probability of malnutrition is higher. Therefore, the incidence of muscle reduction in patients with CRC is significantly higher than that in healthy people, reflecting that the tumor is one of the causes of sarcopenia \[[@CR12]\]. Additionally, sarcopenia is a predictor of adverse outcomes in malignant tumors. Several studies have shown that muscle reduction is closely related to the incidence of postoperative complications and the overall survival of esophagus, gastrointestinal tract, hepatobiliary and pancreatic malignancies \[[@CR13]--[@CR16]\]. However, the impact of sarcopenia on the outcome of GI cancer patients remains controversial due to the heterogeneity of different studies, and negative results have been found in different populations \[[@CR17], [@CR18]\]. Thus, we designed this systematic review and meta-analysis to examine the prevalence of computed tomography (CT)-assessed sarcopenia in GI oncological patients and therefore discuss the relationship between sarcopenia and long-term and short-term outcomes in GI oncological patients.

Methods {#Sec2}
=======

This study was designed based on the preferred reporting items for systematic review and meta-analysis (PRISMA) guidelines \[[@CR19]\].

Search strategy {#Sec3}
---------------

A systematic review and meta-analysis were designed to evaluate CT-assessed sarcopenia in predicting the outcomes of gastrointestinal oncology patients. The Embase, Ovid Medline, Cochrane Database of Systematic Reviews and Cochrane Central Register of Controlled Trials and PubMed were systematically searched up to March 25, 2019. In addition, the gray literature was searched using the related websites and Google Scholar. The keywords were designed by experienced librarians. Briefly, the key words included "sarcopenia", "muscle mass", "body composition" and "gastrointestinal", "gastric", "colorectal", and "neoplasm", "lesion", "tumor", "cancer" in Mesh and keywords. The search strategy is attached in appendix 1. All the studies containing abstracts and titles were imported into Endnote X6 to find duplicate studies and then for literature screening.

Inclusion and exclusion criteria {#Sec4}
--------------------------------

All the studies using CT-assessed sarcopenia or body composition in predicting long-term or short-term outcomes in GI oncology treatment patients were included in our study. The inclusion criteria were as follows: 1) the body composition was assessed by CT; 2) the study had a clear definition for sarcopenia or body composition, with a specific cut-off; 3) the outcome data and clinical data of GI oncological patients could be extracted; 4) GI oncology included esophageal, gastric, intestinal, and colorectal tumors; 5) the study mentioned one or more oncological treatments, such as surgery, chemotherapy, and radiation; 6) the study design was limited to randomized control trials, prospective or retrospective cohort studies, and case-control studies. Meta-analyses, reviews, conference abstracts and comments were read to find more papers. Only the studies written in English were included in the systematic review.

The exclusion criteria were as follows: 1) animal experiments; 2) body composition or sarcopenia assessed by other methods rather than CT; 3) no specific definition or cut-off of sarcopenia or body composition; 4) no available data of outcomes or the prevalence of sarcopenia in GI oncology patients; 5) cancer located in other organs rather than GI systems, such as liver, pancreas, and bladder; and 6) case reports or non-English publications. Data from the same center were treated as one dataset for further meta-analysis.

Literature screening and data extraction {#Sec5}
----------------------------------------

Two investigators (H.Y.S. and T.F.C.) independently screened the abstracts and titles according to the inclusion and exclusion criteria. The full text was further evaluated if the abstract was not definitive. The third investigator (J.X.R.) was consulted for discussion if any disagreement existed.

A standard Excel spreadsheet was designed for data extraction, and the following information was collected from the original studies: the study characteristics (author, publish year, country, institution, recruitment period, study design, etc.), patient characteristics (location of cancer, treatment, total sample, median age, sex distribution, tumor stage, etc.), assessment approach of sarcopenia or body composition (modality, CT-specific index, definition and cut-off of index), sarcopenia prevalence and outcome assessment (complication rate after surgery, toxicity and progression rate after adjuvant therapy, overall survival and disease-free survival after treatment). The complication after surgery was evaluated based on the Clavien-Dindo criteria, and a major complication was defined as stage IIIa or higher \[[@CR20]\].

Quality assessment {#Sec6}
------------------

Two reviewers (E.Y.L. and L.J.S.) independently assessed the quality of the included papers. For case-control and cohort studies, the Newcastle-Ottawa Scale (NOS) was used to evaluate the quality. High quality was defined as a score greater than 7, and moderate quality was defined as a score between 5 and 7 \[[@CR21]\]. Moreover, the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system was used to evaluate the overall quality of the evidence \[[@CR22]\].

Assessment approach of body composition {#Sec7}
---------------------------------------

The CT-quantified muscle mass area was used to assess the sarcopenia. Different criteria, including the skeletal muscle index (SMI), which calculated the area of total skeletal muscle (cm^2^) in the third lumbar (L3) level divided by the height squared (m^2^), total psoas area (TPA), and visceral fat volume and area (VFV, VFA), were commonly used to describe the nutritional status of patients.

Statistical analysis {#Sec8}
--------------------

The statistical analysis was performed by Stata 15.0 software (Stata Corporation, College station, TX, USA). The prevalence of sarcopenia in different studies was drawn in bubble plots, with the relative sample as the bubble size. Linear trends were analyzed using weighted least squares regression using prevalence as the dependent variable and cut-off of SMI in females as the independent variable with sample size as the weight. The complications were compared and combined using relative risk (RR), while the survival analysis was combined using hazard ratio (HR). Both were reported with a 95% confidence interval (CI), and a *P* value less than 0.05 was set as significant. The I^2^ statistic and χ^2^ test were used for heterogeneity assessment (I^2^ ≥ 50% indicating the presence of heterogeneity). When heterogeneity existed, the random-effect model was used, while the fixed-effect model was used otherwise. Finally, forest plots were drawn, and funnel plots were used to evaluate the publication bias.

Results {#Sec9}
=======

Literature selection {#Sec10}
--------------------

A total of 2942 studies were found according to the search strategy. The flowchart is shown in Fig. [1](#Fig1){ref-type="fig"}. After screening the abstracts and titles, 156 studies were scanned in full. After excluding the incompatible studies, a total of 70 studies were included in the systematic review \[[@CR6], [@CR13]--[@CR15], [@CR17], [@CR18], [@CR23]--[@CR86]\]. Fig. 1Flowchart of included studies

Characteristics of the included studies {#Sec11}
---------------------------------------

The characteristics of the included studies are shown in Table [1](#Tab1){ref-type="table"}. The first study using body composition to predict the outcomes after treatment in GI oncological patients was published in 2010 \[[@CR77]\], while the first study using SMI to define sarcopenia was published in 2012 \[[@CR75]\]. Sixty-two studies were retrospective, and eight were prospective, with a recruitment period between 2001 and 2017. A total of 21,875 patients were involved in the systematic review: 1996 esophageal cancer (EC) patients (14 studies), 7913 gastric cancer (GC) patients (27 studies) and 11,875 CRC patients (29 studies). Twelve studies enrolled advanced oncological patients who only received adjuvant treatment, while fifty-seven studies involved patients who underwent surgery combined with adjuvant treatment or not, and the percentage of adjuvant treatment prior or after surgery ranged from 4 to 100%. The median age was 64.6 years (range from 53 to 76 years), and the percentage of male patients ranged from 38 to 92%. The prevalence ranges of tumor stages I, II, and III were 2.78--46.39%, 10.63--56.49%, and 16.12--89.36%. Table 1Characteristics of included studiesAuthorYearRecruitment periodDesignDiseaseTreatmentTotal sampleMedian age, yearTumor stage (AJCC, I/II/III/IV)Male, n (%)Adjuvant therapy, n (%)Yang, J.20192011--2017RetrospectiveCRCSurgery41757.980/190/149/0251 (60)--Hopkins, J. J.20192007--2009RetrospectiveCRCSurgery96865.8100/374/494/0589 (61)503 (52)van Vugt, J. L. A.20182007--2013RetrospectiveCRCSurgery816--255/293/269440 (54)158 (19)van der Kroft, G.20182012--2013RetrospectiveCRCSurgery63--18/13/20/1239 (62)--Mosk, C. A.20182013--2015RetrospectiveCRCSurgery25176--141 (56)26 (10)Mauricio, S. F.20182013--2016RetrospectiveCRCSurgery8461.636/48 ^a^39 (46)51 (61)Martin, L.20182013--2015RetrospectiveCRCSurgery21066.6385/713/887/1091270 (60)--Chen, W. Z.20182014--2017RetrospectiveCRCSurgery37664.365/155/145/11228 (61)--Feliciano, E. M. C.20172006--2011ProspectiveCRCSurgery24763690/806/956/01251 (51)--Black, D.20172006--2014RetrospectiveCRCSurgery33958/153/128/0181 (53)66 (19)Ouchi, A.20162012--2015RetrospectiveCRCSurgery606942/18 ^a^35 (58)--Malietzis, G.20162006--2013RetrospectiveCRCSurgery80569189/265/267/84472 (59)182 (23)Reisinger, K. W.20152010--2012RetrospectiveCRCSurgery310----155 (50)--Park, B. K.20152005--2012RetrospectiveCRCSurgery543--185/314 ^a^311 (57)51 (9)Miyamoto, Y.20152005--2010RetrospectiveCRCSurgery220--77/84/59/054 (25)Huang, D. D.20152014--2015RetrospectiveCRCSurgery14262--88 (62)5 (4)Lieffers, J. R.20122002--2006RetrospectiveCRCSurgery234630/74/83/77135 (58)--Pedziwiatr, M.20162014--2015RetrospectiveCRCSurgery12465.932/32/39/2173 (59)--Jones, K. I.20152011--2012RetrospectiveCRCSurgery10068.6--60 (60)--Guinan, E. M.20182014--2016RetrospectiveECSurgery27------27 (100)Mayanagi, S.20172004--2013ProspectiveECSurgery6663.30/27/39/057 (86)66 (100)Elliott, J. A.20172010--2015RetrospectiveECSurgery20761.6--165 (80)207 (100)Black, D.20172006--2014RetrospectiveECSurgery108--30/43/35/074 (69)65 (60)Nishigori, T.20162005--2014RetrospectiveECSurgery199--33/99/63/6164 (82)--Grotenhuis, B. A.20162001--2012RetrospectiveECSurgery12062--88 (73)120 (100)Yip, C.2014NGRetrospectiveECSurgery35630/10/23/230 (86)35 (100)Nakashima, Y.20182004--2014RetrospectiveECSurgery341--38/46/55/33289 (85)--Paireder, M.20172006--2013RetrospectiveECSurgery13061.415/22/76/3106 (82)130 (100)Tamandl, D.20162006--2013RetrospectiveECSurgery20063.945/33/95/4151 (76)--Harada, K.20162005--2011RetrospectiveECSurgery325--129/45/128/23298 (92)--Tan, B. H.20152010--2012RetrospectiveECSurgery8965.821/27/41/067 (75)89 (100)Zhang, Y.20192015--2017RetrospectiveGCSurgery15659.148/27/81/0115 (74)35 (22)Zhang, W. T.20182014--2016ProspectiveGCSurgery636--203/140/293/0478 (75)--Wang, S. L.20182009--2013RetrospectiveGCSurgery85964239/193/427/0672 (78)--Park, H. S.20182006--2009RetrospectiveGCSurgery136550/57/79/096 (71)63 (46)O'Brien, S.20182008--2014RetrospectiveGCSurgery5668.418/13/18/041 (73)28 (50)Nishigori, T.20182005--2013RetrospectiveGCSurgery177--0/100/77/0127 (72)127 (72)Mao, C. C.20182014--2016ProspectiveGCSurgery68264.6--513 (75)--Lin, J.20182015--2016ProspectiveGCSurgery67065------Choi, M. H.20182007--2009RetrospectiveGCSurgery98--------Beuran, M.20182014--2016RetrospectiveGCSurgery78--6/28/41/13----Zhou, C. J.20172014--2015RetrospectiveGCSurgery2407374/55/111/0190 (79)--Zheng, Z. F.20172009--2013RetrospectiveGCSurgery639--525 (82)408 (64)Lou, N.20172014--2015RetrospectiveGCSurgery20664.180/45/81/0161 (78)--Kudou, K.20172005--2016RetrospectiveGCSurgery148--------Huang, D. D.20172014--2015RetrospectiveGCSurgery47065163/103/204/0364 (77)--Zhuang, C. L.20162008--2013RetrospectiveGCSurgery93764271/219/447730 (78)--Wang, S. L.20162014--2015ProspectiveGCSurgery25565.181/48/126/0190 (75)--Takeuchi, M.20162009--2015RetrospectiveGCSurgery75--25/16/28/657 (76)3 (4)Huang, D. D.20162014--2015ProspectiveGCSurgery1737253/40/80/0135 (78)--Tegels, J. J.20152005--2012RetrospectiveGCSurgery15269.642/27/47/5787 (57)71 (47)Li, X. T.20152005--2008RetrospectiveGCSurgery84570/31/53/060 (71)--Sakurai, K.20172007--2013RetrospectiveGCSurgery56966.7264/121/126/58396 (70)91 (16)Chen, F. F.20162014--2016ProspectiveGCSurgery15866.933/37/88/0126 (80)--Takeda, Y.20182004--2011RetrospectiveRCSurgery144--0/45/99/0102 (71)63 (44)Park, S. E.20182005--2015RetrospectiveRCSurgery65718/24/27/046 (71)65 (100)Choi, M. H.20182009--2013RetrospectiveRCSurgery18861.30/34/154/0117 (62)188 (100)Heus, C.20162006--2013RetrospectiveRCSurgery7464--39 (53)--Souza, B. U.20182015--2016RetrospectiveCRCAll19760.554/138 ^a^112 (57)--Kurk, S. A.2018NGProspectiveCRCAT450----285 (63)n/aChemama, S.20162008--2010RetrospectiveCRCAT9753--37 (38)n/aBlauwhoff-Buskermolen, S.20162011--2014RetrospectiveCRCAT6766.4--42 (63)n/aBarret, M.2014NGRetrospectiveCRCAT5165--38 (75)n/aGuiu, B.20102002--2008RetrospectiveCRCAT120----55 (46)n/aAnandavadivelan, P.20162006--2012RetrospectiveECAT72--2/20/50/0--n/aAwad, S.2012NGRetrospectiveECAT47----34 (72)n/aSugiyama, K.20182013--2015RetrospectiveGCAT11864--59 (50)n/aPalmela, C.20172012--2014RetrospectiveGCAT47680/5/42/032 (68)n/aMirkin, K. A.20172000--2015RetrospectiveGCAT41------n/aHayashi, N.20162009--2014RetrospectiveGCAT53------n/aNipp, R. D.20182011--2015RetrospectiveGICAT103------n/a*Abbreviation*: *EC* esophageal cancer, *GC* gastric cancer, *GIC* gastrointestinal cancer, *CRC* colorectal cancer, *RC* rectal cancer, *AT* adjuvant or neo-adjuvant therapy, *NG* not given, *n/a* not available^a^Tumor stage I and II versus III and IV

Sarcopenia definition, assessment of prevalence {#Sec12}
-----------------------------------------------

The studies were mainly from Asia, Europe, North America, and South America, including 15 counties (Austria, Brazil, Canada, China, France, Ireland, Japan, Korea, Netherland, Poland, Portugal, Romania, Sweden, UK and USA). The common cut-offs for evaluating the sarcopenia are listed in Table [2](#Tab2){ref-type="table"}. The median incidence of sarcopenia was 34.7% (range from 2.1 to 83.3%). The majority of studies (88.4%) used SMI in L3 to assess sarcopenia, five studies used visceral fat criteria, and three studies used TPA criteria. Among the studies using SMI, three main criteria were the most commonly adopted criteria, including 47 studies. The cut-off of SMI introduced by Prado et al. in 2008 (sarcopenia was defined as SMI \< 52.4 cm^2^/m^2^ for males and SMI \< 38.5 cm^2^/m^2^ for females) was used in 20 studies covering 10 countries \[[@CR23], [@CR30], [@CR34], [@CR35], [@CR43]--[@CR45], [@CR47], [@CR52], [@CR57], [@CR61], [@CR62], [@CR64], [@CR67], [@CR69], [@CR73]--[@CR76], [@CR85]\]. The prevalence of sarcopenia ranged from 7.4 to 83.3% (7.4--71.8% in non-Asian countries, with a median prevalence of 40.1%; 14.6--83.3% in Asian countries, with a median prevalence of 52.7%). The cut-off provided by Martin et al. in 2013 (sarcopenia was defined as SMI \< 41 cm^2^/m^2^ in females; SMI \< 53 cm^2^/m^2^ if BMI ≥ 25 kg/m^2^ and SMI \< 43 cm^2^/m^2^ if BMI \< 25 kg/m^2^ in males) was used in 17 studies covering 9 Asian and non-Asian countries \[[@CR6], [@CR24], [@CR28], [@CR31], [@CR33], [@CR35], [@CR37], [@CR38], [@CR42], [@CR50], [@CR54], [@CR58], [@CR65], [@CR66], [@CR68], [@CR81], [@CR82]\]. The prevalence of sarcopenia ranged from 14.7 to 69.8% (14.7--56.7% in non-Asian countries, with a median prevalence of 35.1%; 28.4--69.8% in Asian countries, with a median prevalence of 43.4%). The cut-off introduced by Zhuang et al. was generally used in Asian countries (12 studies: \[[@CR13], [@CR25], [@CR26], [@CR35], [@CR40], [@CR41], [@CR46], [@CR48], [@CR53], [@CR55], [@CR63], [@CR84]\]), which defined sarcopenia as SMI \< 40.8 cm^2^/m^2^ in males and SMI \< 34.9 cm^2^/m^2^ in females, but the majority of the studies were from the same center. The prevalence ranged from 6.8--41.5%, with a median of 23.1%. The cut-off provided by Iritani et al. was used in three studies (SMI \< 36 cm^2^/m^2^ in male; SMI \< 29 cm^2^/m^2^ in female) with a median prevalence of 9.3% \[[@CR35], [@CR59], [@CR72]\], and the cut-off provided by Voron et al. was also used in three studies (SMI \< 55 cm^2^/m^2^ in male; SMI \< 39 cm^2^/m^2^ in female) with a median prevalence of 53.6% \[[@CR36], [@CR79], [@CR80]\]. Two other Japanese studies adopted the cut-off from Sakurai et al. (SMI \< 43.2 cm^2^/m^2^ in males; SMI \< 34.6 cm^2^/m^2^ in females) and had a median prevalence of 23.5% \[[@CR18], [@CR35]\]. The prevalence of sarcopenia is plotted in Fig. [2](#Fig2){ref-type="fig"}, and an increasing trend was found in the prevalence of sarcopenia as the cut-off of SMI increased (β = 0.22, 95% CI = 0.12--0.33, *p* \< 0.001, r^2^ = 0.2170). Table 2Sarcopenia definition, assessment and prevalenceNoModalityIndexCut-off, MaleCut-off, FemaleMethodPrevalenceReferenceCountryNOS1CT/L3SMI32.528.6Cut-off from 3-year overall survival16.1%Zheng, Z. 2017China72CT/L3SMI3629Cut-off from Iritani et al.3.4%Nishigori, T. 2018Japan712.5%Wang, S. 2016China712.0%Huang, D. 2015China83CT/L3SMI40.834.9Cut-off from Zhuang et al.15.4%Zhang, Y. 2019China719.7%Zhang, W. 2018China617.5%Nishigori, T. 2018Japan719.4%Mao, C. 2018China615.5%Lin, J. 2018China524.5%Chen, W. 2018China728.8%Zhou, C. 2017China76.8%Lou, N. 2017China737.4%Huang, D. 2017China741.5%Zhuang, C. 2016China830.1%Huang, D. 2016China724.7%Chen, F. 2016China64CT/L3SMI43.234.6Cut-off from Sakurai et al.22.0%Nishigori, T. 2018Japan725.0%Sakurai, K. 2017Japan85CT/L3SMI44.536.5Cut-off from the third quartile cases25.8%Harada, K. 2016Japan66CT/L3SMI4533.8Cut-off from the third quartile cases25.7%Takeda, Y. 2018Japan77CT/L3SMI47.236.9Cut-off from the median of SMI49.9%Nakashima, Y. 2018Japan88CT/L3SMI4931Cut-off from Kim et al.38.5%Park, S. 2018Korea69CT/L3SMI49.542.1Cut-off from the third quartile cases25.0%Miyamoto, Y. 2015Japan710CT/L3SMI52.438.9Cut-off from Prado et al.14.6%Yang, J. 2019China635.7%O'Brien, S. 2018Ireland764.4%Nishigori, T. 2018Japan77.4%Guinan, E. 2018Ireland439.4%Choi, M. 2018Korea739.8%Choi, M. 2018Korea671.8%Beuran, M. 2018Romania583.3%Mayanagi, S. 2017Japan723.7%Elliott, J. 2017Ireland674.9%Nishigori, T. 2016Japan760.2%Malietzis, G. 2016UK745.0%Grotenhuis, B. 2016Netherlands843.1%Anandavadivelan, P. 2016Swede547.7%Reisinger, K. 2015Netherlands625.7%Yip, C. 2014UK538.9%Lieffers, J. 2012Canada72.1%Awad, S. 2012UK449.4%Tan, B. 2015UK5Sugiyama, K. 2018Japan511CT/L3SMI55.438.9Cut-off from Prado et al.70.6%Barret, M. 2014France512CT/L3SMI5539Cut-off from Voron et al.57.3%Nipp, R. 2018USA438.5%Paireder, M. 2017Austria865.0%Tamandl, D. 2016Austria713CT/L3SMI43/53 (BMI lower or higher than 25)41Cut-off from Martin et al.27.5%Hopkins, J. 2019Canada750.5%van Vugt, J. 2018Netherlands852.4%van der Kroft, G. 2018Netherlands614.7%Souza, B. 2018Brazil432.4%Park, H. 2018Korea642.9%Nishigori, T. 2018Japan724.3%Mosk, C. 2018Netherlands634.5%Mauricio, S. 2018Brazil738.0%Kurk, S. 2018Netherlands423.4%Palmela, C. 2017Portugal428.4%Kudou, K. 2017Japan821.3%Black, D. 2017UK723.9%Black, D. 2017UK740.2%Chemama, S. 2016France656.7%Blauwhoff-Buskermolen, S. 2016Netherlands656.6%Tegels, J. 2015Netherlands627.4%Pedziwiatr, M. 2016Poland769.8%Hayashi, N. 2016Japan614CT/L3SMI52/54 (BMI lower or higher than 30)38/47 (BMI lower or higher than 30)Cut-off from Caan et al.45.9%Feliciano, E. 2017USA615CT/L3SMI----z-score below - 0.5 for SMI in different ages6.7%Martin, L. 2018Canada616CT/L3TPA538346normal TPA in the lowest sex-specific quartile33.3%Ouchi, A. 2016Japan617CT/L3TPA545385Cut-off from Fearon et al.29.3%Mirkin, K. 2017USA515.0%Jones, K. 2015UK418CTVEV1.921.92Cut-off from the quartiles25.0%Park, B. 2015Korea519CTVFA100100Cut-off from the Japanese Society for study of Obesity35.9%Wang, S. 2018China765.3%Takeuchi, M. 2016Japan640.5%Heus, C. 2016Netherlands4*Abbreviation*: *CT/L3* the third lumbar vertebra level in CT scan, *BMI* body mass index, *SMI* skeletal muscle index, *TPA* total psoas muscle area, *VEV* visceral fat volume, *VFA* visceral fat area Fig. 2The bubble plots and linear relationship between the prevalence of sarcopenia and the cut-offs for females under different criteria (A. cut-off from Iritani et al.; B. cut-off from Zhuang et al.; C. cut-off from Prado et al.; D. cut-off from Martin et al.)

Quality assessment {#Sec13}
------------------

The quality assessment is available in Table [2](#Tab2){ref-type="table"} and shows the study quality ranging from low to high quality, with scores ranging from 4 to 8 on the NOS scale. Eight studies were considered high quality, with a score of 8 \[[@CR13], [@CR18], [@CR28], [@CR54], [@CR64], [@CR72], [@CR78], [@CR79]\], fifty-three studies were considered moderate quality, with a score ranging from 5 to 7 \[[@CR6], [@CR15], [@CR17], [@CR23]--[@CR27], [@CR29], [@CR30], [@CR32]--[@CR35], [@CR37]--[@CR41], [@CR44]--[@CR49], [@CR51]--[@CR53], [@CR55]--[@CR63], [@CR65]--[@CR71], [@CR73]--[@CR75], [@CR80]--[@CR85]\], and the remaining 9 studies were given a score of 4 and considered low quality \[[@CR14], [@CR31], [@CR36], [@CR42], [@CR43], [@CR50], [@CR76], [@CR77], [@CR86]\]. According to the GRADE, the overall quality of the evidence of sarcopenia as a predictive factor for both long-term and short-term should be considered "very low" due to the lack of randomized control trials.

Long-term outcome assessment {#Sec14}
----------------------------

The forest plot of long-term outcomes after surgery in GI oncology patients is shown in Fig. [3](#Fig3){ref-type="fig"}. A total of 20 studies were included for assessing the risk for overall survival (OS) (Fig. [3](#Fig3){ref-type="fig"}a), and 11 studies were included for disease-free survival (DFS) (Fig. [3](#Fig3){ref-type="fig"}b). The preoperative incidence of sarcopenia was associated both with an increased risk of overall mortality (HR = 1.602, 95% CI = 1.369--1.873, *P* \< 0.001, I^2^ = 59.5%, random-effect model) and disease-free mortality (HR = 1.461, 95% CI = 1.297--1.646, P \< 0.001, I^2^ = 0%, fixed-effect model). Fig. 3The forest plot for assessing the impact of sarcopenia on long-term outcomes (**a**. overall survival; **b**. disease-free survival)

The subgroup analysis is shown in Table [3](#Tab3){ref-type="table"}. Due to the different body shapes, we compared the Asian countries and non-Asian countries. Moreover, three main criteria and three main diseases, CRC, EC and GC, were compared. In terms of OS, the preoperative incidence of sarcopenia was associated with higher overall mortality in both Asian and non-Asian populations (HR = 1.776 and 1.368, *P* \< 0.001 and *P* = 0.002, respectively). Preoperative sarcopenia using cut-offs provided by Zhang et al. and Martin et al. increased the risk of overall mortality (HR = 1.622 and 1.343, respectively, both *P* \< 0.001), while no statistically significant increase was observed using the cut-off provided by Prado et al. (HR = 1.976, *P* = 0.075). In terms of the tumor in the three different locations, preoperative sarcopenia was always a risk factor increasing the overall mortality (HR = 1.523, 1.567, and 1.703, *P* = 0.001, 0.015 and \< 0.001 in CRC, EC and GC surgical patients, respectively). In terms of DFS, the preoperative incidence of sarcopenia was also associated with a higher risk of disease-free mortality in both Asian and non-Asian populations (*P* \< 0.001 and *P* = 0.037, respectively). Similarly, both cut-offs provided by Zhang et al. and Martin et al. were available for defining sarcopenia for predicting the disease-free survival (P \< 0.001 and *P* = 0.028). In addition, preoperative sarcopenia was predive for DFS in both CRC and GC surgical patients (*P* = 0.011 and *P* \< 0.001, respectively). Only one study focused on EC surgical patients, and this had no statistical significance in predicting DFS (*P* = 0.235). Table 3The results of subgroup meta-analysisSubgroupCohortHR or RR95%CIP valueI2Long-term outcome (HR)-Overall survival Overall201.6021.369--1.873\< 0.00159.5% Asian countries121.7761.556--2.026\< 0.00141.9% Non-Asian countries81.3681.117--1.6760.00260.1% Zhuang criteria21.6221.326--1.983\< 0.0010% Martin criteria51.3431.200--1.503\< 0.0010% Prado criteria61.9760.934--4.1820.07574.2% CRC surgery71.5231.201--1.9300.00163.1% EC surgery51.5671.089--2.2530.01552.9% GC surgery81.7031.281--2.262\< 0.00160.6%Long-term outcome (HR)-Disease-free survival Overall111.4611.297--1.646\< 0.0010% Asian countries91.5661.357--1.808\< 0.0010% Non-Asian countries21.2551.014--1.5530.0370% Zhuang criteria21.5681.274--1.930\< 0.0010% Martin criteria31.2491.024--1.5230.0280% Prado criteria31.2710.778--2.0750.3380% CRC surgery41.2821.058--1.5540.0110% EC surgery12.0600.626--6.7830.235-- GC surgery61.5781.355--1.839\< 0.0010%Short-term outcome (RR)-Total complication after surgery Overall151.1881.083--1.303\< 0.00126.4% Asian countries101.1651.046--1.2980.00543.9% Non-Asian countries51.2521.045--1.4990.0150% Zhuang criteria41.4231.214--1.667\< 0.0010% Martin criteria51.2461.017--1.5270.0340% Prado criteria21.0740.842--1.3710.5650% CRC surgery61.3141.101--1.5680.0020% EC surgery41.0510.900--1.2260.5310% GC surgery51.2181.046--1.4190.01161.9%Short-term outcome (RR)-Major complication after surgery Overall141.2281.042--1.4480.01412.1% Asian countries71.2441.001--1.5450.04945.9% Non-Asian countries71.2060.936--1.5530.1480% Zhuang criteria22.0841.359--3.1960.00150% Martin criteria50.9880.690--1.4130.9460% Prado criteria41.3090.978--1.7500.0700% CRC surgery40.8990.545--1.4810.6750% EC surgery41.1810.932--1.4950.1690% GC surgery61.3931.076--1.8030.01248.3%*Abbreviation*: *RR* relative risk, *HR* hazard ratio, *CI* confidence interval, *EC* esophageal cancer, *GC* gastric cancer, *CRC* colorectal cancer

Short-term outcome assessment {#Sec15}
-----------------------------

The forest plot of postoperative short-term complications is shown in Fig. [4](#Fig4){ref-type="fig"} (A, total complications; B, major complications). A total of 15 studies reported 1498 postoperative complications occurring in 6489 patients and found that preoperative sarcopenia was a risk factor for total complications (RR = 1.188, 95% CI = 1.083--1.303, P \< 0.001, I^2^ = 26.4%, fixed-effect model). Moreover, based on 14 studies with 526 major complications in 4204 patients, the preoperative incidence of sarcopenia was associated with a higher risk of major complications (RR = 1.228, 95% CI = 1.042--1.448, *P* = 0.014, I^2^ = 12.1%, fixed-effect model). Fig. 4The forest plot in assessing the impact of sarcopenia on short-term outcomes (**a**. total complication; **b**. major complication)

In the subgroup analysis, preoperative sarcopenia was associated with a high risk of total complications in both Asian and non-Asian populations (*P* = 0.005 and *P* = 0.015), while only a slightly significantly higher risk of major complications in Asian populations (*P* = 0.049) and no significantly higher risk in non-Asian populations were found (*P* = 0.148). Preoperative sarcopenia using cut-off provided by Zhuang et al. was a risk factor for increasing both total and major complications after surgery (*P* \< 0.001 and *P* = 0.001), while there was no predictive value when using the cut-off from Prado et al. (*P* \> 0.05). Sarcopenia was associated with total complications but not any major complication when using the cut-off provided by Martin et al. (*P* = 0.034 and *P* = 0.946). Preoperative sarcopenia was a risk factor in total and major complications after GC surgery (*P* = 0.011 and *P* = 0.012), but not EC surgery (*P* = 0.531 and *P* = 0.169). Sarcopenia was a risk factor for total complications after CRC surgery (*P* = 0.002), but not major complications (*P* = 0.675).

Discussion {#Sec16}
==========

This is the largest-scale systematic review and includes 70 studies to discuss the impact of CT-assessed sarcopenia on GI oncological patients. Our meta-analysis demonstrated that the prevalence of sarcopenia increased with the cut-off of CT-assessed SMI. Preoperative sarcopenia was associated with both long-term outcomes and short-term outcomes. More studies still need to be performed to demonstrate its efficacy in different populations, criteria and diseases.

The impact of nutrition status on oncological patients has been a research hot spot in recent years \[[@CR33], [@CR84]\]. Sarcopenia, defined as an age-related muscle reduction disease, has been discussed and updated over time, while the measurement and criteria still need to be determined \[[@CR23], [@CR87]\]. It is believed that sarcopenia is a syndrome in which the risk of adverse events is increased with a decrease in skeletal muscle mass associated with decreased muscle strength or function \[[@CR87]\]. Because of its objectivity, repeatability, and accuracy, CT is widely used to measure muscle mass, with errors ranging from 1 to 4%, and thus it is considered a "gold standard" \[[@CR69], [@CR88]\]. Usually, the L3 muscle area is measured due to its accuracy reflecting the "real" muscle mass and fat volume \[[@CR89]\]. Patients undergoing elective GI cancer surgery routinely undergo abdominal CT assessment of the patient's tumor staging without additional costs. In China, the interval between CT examination and surgery is usually used to optimize the patient's preoperative status and does not lead to delays in treatment. These optimizations include preoperative nutritional screening and support, physical functioning, pre-rehabilitation, and improvement of comorbidities \[[@CR90]\].

Undoubtedly, the incidence of sarcopenia depends mostly on how to define the diagnostic cut-off point for sarcopenia. In our systematic review, a total 19 criteria were used to define sarcopenia. We found that the incidence of SMI was higher when the cut-off of SMI was raised. When using the Western criteria provided by Prado et al. and Martin et al., the incidence of sarcopenia was always higher for the Asian populations, which could be one heterogeneity because of the difference in body shape and diet habit \[[@CR89], [@CR91]\]. Although some Asian criteria were proposed, such as by Zhuang et al., Iritani et al. and Kim et al., the validation among countries still needs to be investigated for efficacy and accuracy \[[@CR13], [@CR92], [@CR93]\].

Aging is a process in which all functions of the body are declining. Although current research has clarified the relationship between sarcopenia and aging, the specific primary pathogenic factors remain unclear and may be related to a series of changes caused by aging \[[@CR7], [@CR10]\]. The number of motor neurons in those over 70 years old is greatly reduced, and skeletal muscle mass begins to shrink at age 30 \[[@CR12]\]. Studies have found that sarcopenia is mainly related to the decrease in the number of type II muscle fibers, which is reduced by up to 40% in patients over 70. This could explain why elders are more prone to falls \[[@CR26]\]. In our meta-analysis, we demonstrated that preoperative sarcopenia might increase by 1.1--1.2-fold the risk of total and major complications in GI patients. Patients suffering from sarcopenia may feel weak, with limited mobility, which in turn affects the postoperative recovery process. However, until now, there was no evidence to demonstrate that preoperative increase in muscle mass could improve the outcome of GI oncological patients. One reason is that the short period during cancer diagnosis and surgery might not be enough to improve nutritional status. Most older people have insufficient protein intake or absorption barriers. Moreover, with the nutrition consumption in tumors, malnutrition and weight loss are common problems in GI malignancy patients. It not only affects hospitalization time and costs but also affects the quality of life and long-term survival of patients. Therefore, preoperative sarcopenia may be associated with postoperative complications. Early identification of the onset of sarcopenia in the elderly population and early intervention may help the patient maintain muscle mass and improve patient outcomes during treatment. Nutritional support therapy can improve the prognosis of hospitalized patients, but there is controversy about the improvement of muscle mass and function, while exercise is beneficial in the maintenance of human physiological functions \[[@CR94]\]. The American Cancer Society (ACS) has recommended clinical activities for all cancer patients based on clinical research on aerobic exercise and resistance training in recent decades. Age-related muscle mass and muscle strength reduction also depend on individual health status, heredity, activity function, muscle mass and muscle strength training, and nutritional levels \[[@CR12]\]. Patients with sedentary movements have a more pronounced decrease in the number and intensity of muscle fibers compared with patients with normal activities, revealing that exercise can slow muscle atrophy. Active exercise combined with essential amino acid nutrition support can improve muscle status and is an effective way to fight muscle deficiency \[[@CR95]\].

Most studies currently focus only on the relationship between sarcopenia and clinical outcomes and rarely explore the causes. Studies have found that muscle reduction reflects an increase in the metabolism of malignant tumors, resulting in an increased systemic inflammatory response and increased muscle consumption \[[@CR96]\]. Moreover, several studies found that a systemic inflammatory response significantly increased the adverse outcomes of patients \[[@CR97], [@CR98]\]. Richards et al. found a clear correlation between muscle reduction in patients with resectable primary CRC and systemic inflammatory response \[[@CR97]\]. Aleman et al. suggested that inflammatory cells may participate in the onset of sarcopenia by interfering with the skeletal muscle insulin-like growth factor-I pathway \[[@CR98]\]. This may explain why the poor prognosis in sarcopenia may be related to an increase in the systemic inflammatory response. Sarcopenia may also be affected by genetic factors. A genome-wide association study found that genes associated with sarcopenia and osteoporosis include growth differentiation factor 8, myocyte enhancer factor 2C, and peroxisome proliferator receptor gamma coactivator 1a. There are currently few reports on the genetics of sarcopenia, and further research is still needed \[[@CR99]\].

There were some limitations to our study. First, due to the observational nature of the available studies, the evidence was "low quality" by the GRADE criteria. More prospective randomized control trials need to be performed to investigate the efficacy of sarcopenia in predicting outcomes in oncological patients. Second, due to the heterogeneity existing due to the different cut-offs and diseases, the included studies had few subgroup analyses. Third, the Clavien-Dindo classification is suitable for assessing postoperative complications, while sarcopenia may be associated with some specific complications, such as respiratory complications, infectious complications and postoperative leakage, which could not be calculated in every included study. Further efforts need to be made in individual patient meta-analyses and regressions to discuss the risk of sarcopenia in oncological patients.

Conclusion {#Sec17}
==========

The prevalence of sarcopenia increases when the cut-off of SMI increases. The preoperative incidence of sarcopenia is a risk factor for both overall and disease-free survival and short-term total and major postoperative complications in the whole population of gastrointestinal oncology patients. In the subgroup analysis, sarcopenia is related to higher complication, recurrence and mortality rates in CRC and GC surgical patients. The cut-off provided by Martin et al. is the most common predictable criteria globally, while more Western cohorts need to be validated when using cut-offs provided by Asian countries.
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